Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
123.40    -0.40 (-0.32%)
Bid:
123.00
Ask:
123.60
Spread: 0.60 (0.488%)
Market Cap: £300.38m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Form 8.5 (EPT/RI)

10 Oct 2022 09:18

RNS Number : 3204C
Liberum Capital Limited
10 October 2022
 

 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Liberum Capital Limited

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PureTech Health plc

(c) Name of the party to the offer with which exempt principal trader is connected:

PureTech Health plc

(d) Date dealing undertaken:

07th October 2022

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

No

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 25p

 

 

Purchase

 

14,664

 

2.21

 

2.2

 

ORD 25p

 

 

Sale

 

14,664

 

2.21

 

2.2

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

10th October 2022

 

Contact name:

Kristina Kapur

Telephone number:

020 3100 2034

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERGIBDGLBBDGDG
Date   Source Headline
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting
23rd Jun 20207:00 amRNSAkili Gets European Approval to Market EndeavorRx
22nd Jun 20202:00 pmRNSPRTC Presents New Immuno-oncology Data at AACR
22nd Jun 20207:00 amRNSPDMR Notification RSU Vesting
18th Jun 202012:01 pmRNSGelesis China Deal $35M and up to $388M milestones
16th Jun 20207:00 amRNSAkili Granted FDA Clearance for ADHD Treatment
15th Jun 202012:07 pmRNSSecond Price Monitoring Extn
15th Jun 202012:02 pmRNSPrice Monitoring Extension
12th Jun 202012:08 pmRNSSecond Price Monitoring Extn
12th Jun 202012:03 pmRNSPrice Monitoring Extension
12th Jun 20207:00 amRNSResult of AGM
10th Jun 202012:08 pmRNSSecond Price Monitoring Extn
10th Jun 202012:02 pmRNSPrice Monitoring Extension
9th Jun 20207:00 amRNSPositive Data from Vedanta IBD Clinical Studies
4th Jun 20207:00 amRNSPositive FDA Feedback on Follica
2nd Jun 20207:00 amRNSGelesis Approved to Market Plenity in Europe
28th May 20207:00 amRNSPRTC Targets COVID-19 Post-Recovery Complications
27th May 20207:00 amRNSPRTC to Present at Jefferies Virtual Conference
26th May 20201:05 pmRNSVor Appoints CFO Nathan Jorgensen
26th May 20207:00 amRNSPRTC Receives Another $45M from Affiliate Shares
22nd May 202012:02 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:05 amRNSPDMR DEALING - PURCHASE OF SHARES
20th May 20207:00 amRNSPDMR Notification – Transfer From Trust
19th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 202012:02 pmRNSPrice Monitoring Extension
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
18th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
15th May 20207:00 amRNSPDMR DEALING - PURCHASE OF SHARES
6th May 202012:07 pmRNSSecond Price Monitoring Extn
6th May 202012:02 pmRNSPrice Monitoring Extension
4th May 202012:02 pmRNSPrice Monitoring Extension
23rd Apr 202012:07 pmRNSSecond Price Monitoring Extn
23rd Apr 202012:03 pmRNSPrice Monitoring Extension
22nd Apr 202011:00 amRNSAkili ADHD Treatment Now Available in US
21st Apr 20204:41 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 202012:07 pmRNSSecond Price Monitoring Extn
21st Apr 202012:02 pmRNSPrice Monitoring Extension
14th Apr 20207:00 amRNSPRTC to Present at Virtual Needham Conference
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.